D.A. Davidson Sticks to Its Buy Rating for Amazon (AMZN)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Luria is a 5-star analyst with an average return of 16.1% and a 60.74% success rate. Luria covers the Technology sector, focusing on stocks such as Adobe, CoreWeave, Inc. Class A, and ServiceNow.
Amazon has an analyst consensus of Strong Buy, with a price target consensus of $262.55, a 12.15% upside from current levels. In a report released today, TD Cowen also maintained a Buy rating on the stock with a $255.00 price target.
AMZN market cap is currently $2485.4B and has a P/E ratio of 38.18.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
38 minutes ago
- Globe and Mail
Strategy Announces $4.2 Billion Stock Sales Agreement
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Strategy ( (MSTR)) has shared an announcement. On July 31, 2025, Strategy announced a sales agreement with several agents to issue and sell shares of its Variable Rate Series A Perpetual Stretch Preferred Stock, with an aggregate offering price of up to $4.2 billion. The company plans to use the proceeds for general corporate purposes, including the acquisition of Bitcoin and working capital. The sales will be conducted as an 'at the market offering' and are subject to terms and conditions outlined in the sales agreement. This move is part of Strategy's broader strategy to leverage its position in the digital asset market and enhance its financial flexibility. The most recent analyst rating on (MSTR) stock is a Buy with a $392.00 price target. To see the full list of analyst forecasts on Strategy stock, see the MSTR Stock Forecast page. Spark's Take on MSTR Stock According to Spark, TipRanks' AI Analyst, MSTR is a Neutral. The overall stock score of 48 reflects significant financial and valuation challenges, with high leverage and negative earnings outweighing positive strategic initiatives and Bitcoin-focused capital strategies. Despite a strong strategic focus on cryptocurrency and recent successful capital raising, the financial instability and legal risks pose substantial concerns. To see Spark's full report on MSTR stock, click here. More about Strategy MicroStrategy Incorporated, doing business as Strategy, is a publicly traded company recognized as the world's first and largest Bitcoin Treasury Company. It has adopted Bitcoin as its primary treasury reserve asset and strategically accumulates Bitcoin through equity and debt financings, as well as cash flows from operations. The company also provides AI-powered enterprise analytics software, integrating analytics expertise with digital asset growth, positioning itself as a leader in both the digital asset and enterprise analytics sectors. Average Trading Volume: 12,259,375 Technical Sentiment Signal: Buy Current Market Cap: $111.9B See more data about MSTR stock on TipRanks' Stock Analysis page.
CBC
2 hours ago
- CBC
Lawyer breaks down legal fight over Trump's tariffs
U.S. President Donald Trump's use of emergency powers to impose across-the-board tariffs on trading partners came under sharp questioning from federal appellate court judges. Robert Glasgow, partner with McCarthy Tetrault LLP, talks about the legal challenges to Trump's authority to impose tariffs.
Globe and Mail
2 hours ago
- Globe and Mail
AstraZeneca's AZD3427 Study: A Potential Game-Changer for Heart Failure and Pulmonary Hypertension
AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca, in collaboration with Parexel International, is conducting a Phase IIb study titled A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Due to Left Heart Disease (WHO Group 2). The study aims to assess the efficacy of AZD3427 in reducing pulmonary vascular resistance in patients with heart failure and pulmonary hypertension over 24 weeks, highlighting its potential significance in treating these conditions. The intervention being tested is AZD3427, administered as a subcutaneous injection. It is designed to target pulmonary hypertension by reducing vascular resistance, with the study evaluating three different dose levels of the drug. The study follows a randomized, parallel assignment model with triple masking, involving participants, care providers, and investigators. Its primary purpose is treatment-focused, aiming to determine the optimal dosing strategy for AZD3427. The study began on April 24, 2023, with an estimated completion date in July 2025. These timelines are crucial for tracking the progress and potential market introduction of AZD3427. The outcome of this study could significantly impact AstraZeneca's market position, potentially boosting its stock performance if results are positive. Investors will be keenly watching for updates, especially in the context of competitive treatments for heart failure and pulmonary hypertension. The study is ongoing, with further details available on the ClinicalTrials portal.
